PPARγ and the global map of adipogenesis and beyond

Trends in Endocrinology and Metabolism

Volumn 25, Issue 6, 2014, Pages 293-302

  Lefterova, Martina I ^a,b   Haakonsson, Anders K ^c   Lazar, Mitchell A ^b   Mandrup, Susanne ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Adipogenesis; Chromatin; Genome wide analyses; PPAR ; Transcriptional network

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; STAT5A PROTEIN; CHROMATIN;

ADIPOGENESIS; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GLUCOSE INTOLERANCE; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; POSITION WEIGHT MATRIX; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHROMATIN; GENETICS; METABOLISM; PHYSIOLOGY;

ADIPOGENESIS; ANIMALS; CHROMATIN; HUMANS; PPAR GAMMA;

EID: 84901820044     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.04.001     Document Type: Review

References (107)

1. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 2008, 77:289-312.
2. Ahmadian M., et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat. Med. 2013, 19:557-566.
3. Poulsen L., et al. PPARs: fatty acid sensors controlling metabolism. Semin. Cell Dev. Biol. 2012, 23:631-639.
4. Siersbæk R., et al. PPARgamma in adipocyte differentiation and metabolism - novel insights from genome-wide studies. FEBS Lett. 2010, 584:3242-3249.
5. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123:993-999.
6. Cariou B., et al. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol. Metab. 2012, 23:205-215.
7. Tang Q.Q., Lane M.D. Adipogenesis: from stem cell to adipocyte. Annu. Rev. Biochem. 2012, 81:715-736.
8. Siersbæk R., et al. Transcriptional networks and chromatin remodeling controlling adipogenesis. Trends Endocrinol. Metab. 2012, 23:56-64.
9. Lefterova M.I., Lazar M.A. New developments in adipogenesis. Trends Endocrinol. Metab. 2009, 20:107-114.
10. Rosen E.D., Spiegelman B.M. What we talk about when we talk about fat. Cell 2014, 156:20-44.
11. Steger D.J., et al. Propagation of adipogenic signals through an epigenomic transition state. Genes Dev. 2010, 24:1035-1044.
12. Lefterova M.I., et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 2008, 22:2941-2952.
13. Nielsen R., et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 2008, 22:2953-2967.
14. Hamza M.S., et al. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS ONE 2009, 4:e4907.
15. Wakabayashi K., et al. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Mol. Cell. Biol. 2009, 29:3544-3555.
16. Mikkelsen T.S., et al. Comparative epigenomic analysis of murine and human adipogenesis. Cell 2010, 143:156-169.
17. Hsu M.H., et al. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J. Biol. Chem. 1998, 273:27988-27997.
18. Chandra V., et al. Structure of the intact PPAR-gamma-RXR nuclear receptor complex on DNA. Nature 2008, 456:350-356.
19. IJpenberg A., et al. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J. Biol. Chem. 1997, 272:20108-20117.
20. Palmer C.N., et al. Novel sequence determinants in peroxisome proliferator signaling. J. Biol. Chem. 1995, 270:16114-16121.
21. Haakonsson A.K., et al. Acute genome-wide effects of rosiglitazone on PPARgamma transcriptional networks in adipocytes. Mol. Endocrinol. 2013, 27:1536-1549.
22. Schmidt S.F., et al. Cross species comparison of C/EBPalpha and PPARgamma profiles in mouse and human adipocytes reveals interdependent retention of binding sites. BMC Genomics 2011, 12:152.
23. Bolton E.C., et al. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007, 21:2005-2017.
24. Gao H., et al. Genome-wide identification of estrogen receptor alpha-binding sites in mouse liver. Mol. Endocrinol. 2008, 22:10-22.
25. Lupien M., et al. Coactivator function defines the active estrogen receptor alpha cistrome. Mol. Cell. Biol. 2009, 29:3413-3423.
26. Yu C.Y., et al. Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLoS ONE 2010, 5:e15188.
27. Deschenes J., et al. Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20kb of upstream flanking sequences. J. Biol. Chem. 2007, 282:17335-17339.
28. Fullwood M.J., et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462:58-64.
29. Bugge A., et al. A novel intronic peroxisome proliferator-activated receptor gamma enhancer in the uncoupling protein (UCP) 3 gene as a regulator of both UCP2 and -3 expression in adipocytes. J. Biol. Chem. 2010, 285:17310-17317.
30. Kieffer-Kwon K.R., et al. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell 2013, 155:1507-1520.
31. Madsen M.S., et al. Peroxisome proliferator-activated receptor gamma and C/EBPalpha synergistically activate key metabolic adipocyte genes by assisted loading. Mol. Cell. Biol. 2014, 34:939-954.
32. Vernochet C., et al. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol. Cell. Biol. 2009, 29:4714-4728.
33. Step S., et al. Antidiabetic rosiglitazone remodels the adipocyte transcriptome by concentrating transcription onto PPARg-driven enhancers. Genes Dev. 2014, (in press).
34. Clapier C.R., Cairns B.R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 2009, 78:273-304.
35. Crawford G.E., et al. Genome-wide mapping of DNase hypersensitive sites using massively parallel signature sequencing (MPSS). Genome Res. 2006, 16:123-131.
36. Boyle A.P., et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008, 132:311-322.
37. Stitzel M.L., et al. Global epigenomic analysis of primary human pancreatic islets provides insights into type 2 diabetes susceptibility loci. Cell Metab. 2010, 12:443-455.
38. John S., et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 2011, 43:264-268.
39. Thurman R.E., et al. The accessible chromatin landscape of the human genome. Nature 2012, 489:75-82.
40. Siersbæk R., et al. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 2011, 30:1459-1472.
41. Waki H., et al. Global mapping of cell type-specific open chromatin by FAIRE-seq reveals the regulatory role of the NFI family in adipocyte differentiation. PLoS Genet. 2011, 7:e1002311.
42. Lee J.E., et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife 2013, 2:e01503.
43. Oger F., et al. Peroxisome proliferator-activated receptor gamma regulates genes involved in insulin/insulin-like growth factor signaling and lipid metabolism during adipogenesis through functionally distinct enhancer classes. J. Biol. Chem. 2014, 289:708-722.
44. Wang L., et al. Histone H3K9 methyltransferase G9a represses PPARgamma expression and adipogenesis. EMBO J. 2013, 32:45-59.
45. Siersbæk R., et al. Transcription factor cooperativity in early adipogenic hotspots and super-enhancers. Cell Rep. 2014, (in press).
46. Siersbæk M.S., et al. Genome-wide profiling of peroxisome proliferator-activated receptor gamma in primary epididymal, inguinal, and brown adipocytes reveals depot-selective binding correlated with gene expression. Mol. Cell. Biol. 2012, 32:3452-3463.
47. Tran T.T., et al. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab. 2008, 7:410-420.
48. Lee M.J., et al. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol. Aspects Med. 2013, 34:1-11.
49. Tchkonia T., et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 2013, 17:644-656.
50. Rajakumari S., et al. EBF2 determines and maintains brown adipocyte identity. Cell Metab. 2013, 17:562-574.
51. Schmitz G., Grandl M. Lipid homeostasis in macrophages - implications for atherosclerosis. Rev. Physiol. Biochem. Pharmacol. 2008, 160:93-125.
52. Moore K.J., et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 2001, 7:41-47.
53. Huang J.T., et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400:378-382.
54. Odegaard J.I., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
55. Lumeng C.N., et al. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
56. Lumeng C.N., et al. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E166-E174.
57. Lumeng C.N., et al. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56:16-23.
58. Odegaard J.I., Chawla A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:619-626.
59. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011, 11:750-761.
60. Hevener A.L., et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117:1658-1669.
61. Chawla A., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 2001, 7:161-171.
62. Lefterova M.I., et al. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. Mol. Cell. Biol. 2010, 30:2078-2089.
63. Pott S., et al. PPARG binding landscapes in macrophages suggest a genome-wide contribution of PU.1 to divergent PPARG binding in human and mouse. PLoS ONE 2012, 7:e48102.
64. Pascual G., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
65. Ghisletti S., et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 2007, 25:57-70.
66. Gallardo-Soler A., et al. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Mol. Endocrinol. 2008, 22:1394-1402.
67. Bouhlel M.A., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6:137-143.
68. Nencioni A., et al. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J. Immunol. 2002, 169:1228-1235.
69. Klotz L., et al. Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1. J. Immunol. 2009, 183:129-136.
70. Simon M.C., et al. Terminal myeloid gene expression and differentiation requires the transcription factor PU.1. Curr. Top. Microbiol. Immunol. 1996, 211:113-119.
71. Friedman A.D. Transcriptional control of granulocyte and monocyte development. Oncogene 2007, 26:6816-6828.
72. Dispirito J.R., et al. Pruning of the adipocyte peroxisome proliferator-activated receptor gamma cistrome by hematopoietic master regulator PU.1. Mol. Cell. Biol. 2013, 33:3354-3364.
73. Buecker C., Wysocka J. Enhancers as information integration hubs in development: lessons from genomics. Trends Genet. 2012, 28:276-284.
74. Guan H.P., et al. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 2005, 19:453-461.
75. Zhang H., et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9406-9411.
76. Vallon V., et al. Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J. Am. Soc. Nephrol. 2009, 20:721-729.
77. Panchapakesan U., et al. Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology 2009, 14:298-301.
78. Saad S., et al. The role of Sgk-1 in the upregulation of transport proteins by PPAR-γ agonists in human proximal tubule cells. Nephrol. Dial. Transplant. 2009, 24:1130-1141.
79. Yang J., et al. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clin. Sci. (Lond.) 2009, 116:17-26.
80. Wan Y. PPARgamma in bone homeostasis. Trends Endocrinol. Metab. 2010, 21:722-728.
81. Akune T., et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 2004, 113:846-855.
82. Wan Y., et al. PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 2007, 13:1496-1503.
83. Melnikov A., et al. Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat. Biotechnol. 2012, 30:271-277.
84. Soccio R.E., et al. Species-specific strategies underlying conserved functions of metabolic transcription factors. Mol. Endocrinol. 2011, 25:694-706.
85. Schmidt S.F., et al. Cross-species ChIP-seq studies provide insights into regulatory strategies of PPARgamma in adipocytes. Transcription 2012, 3:19-24.
86. Wilson M.D., et al. Species-specific transcription in mice carrying human chromosome 21. Science 2008, 322:434-438.
87. Schmidt D., et al. Five-vertebrate ChIP-seq reveals the evolutionary dynamics of transcription factor binding. Science 2010, 328:1036-1040.
88. Kunarso G., et al. Transposable elements have rewired the core regulatory network of human embryonic stem cells. Nat. Genet. 2010, 42:631-634.
89. Odom D.T., et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat. Genet. 2007, 39:730-732.
90. Green H., Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell 1975, 5:19-27.
91. Green H., Meuth M. An established pre-adipose cell line and its differentiation in culture. Cell 1974, 3:127-133.
92. Chawla A., et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994, 135:798-800.
93. Tontonoz P., et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994, 8:1224-1234.
94. Tontonoz P., et al. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res. 1994, 22:5628-5634.
95. Barak Y., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4:585-595.
96. Rosen E.D., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 1999, 4:611-617.
97. Jones J.R., et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:6207-6212.
98. Wang F., et al. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARgamma. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18656-18661.
99. Imai T., et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4543-4547.
100. Bugge A., et al. The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment. Mol. Endocrinol. 2009, 23:794-808.
101. Grontved L., et al. MED14 tethers mediator to the N-terminal domain of peroxisome proliferator-activated receptor gamma and is required for full transcriptional activity and adipogenesis. Mol. Cell. Biol. 2010, 30:2155-2169.
102. Schupp M., Lazar M.A. Endogenous ligands for nuclear receptors: digging deeper. J. Biol. Chem. 2010, 285:40409-40415.
103. Lago R.M., et al. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
104. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 2010, 170:1191-1201.
105. Neumann A., et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012, 55:1953-1962.
106. Mahaffey K.W., et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am. Heart J. 2013, 166:240-249.
107. Norris A.W., Sigmund C.D. A second chance for a PPARgamma targeted therapy?. Circ. Res. 2012, 110:8-11.